Braykov Nikolay P, Morgan Daniel J, Schweizer Marin L, Uslan Daniel Z, Kelesidis Theodoros, Weisenberg Scott A, Johannsson Birgir, Young Heather, Cantey Joseph, Srinivasan Arjun, Perencevich Eli, Septimus Edward, Laxminarayan Ramanan
Center for Disease Dynamics, Economics and Policy, Washington, DC, USA.
Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Lancet Infect Dis. 2014 Dec;14(12):1220-7. doi: 10.1016/S1473-3099(14)70952-1. Epub 2014 Nov 17.
Modification of empirical antimicrobials when warranted by culture results or clinical signs is recommended to control antimicrobial overuse and resistance. We aimed to assess the frequency with which patients were started on empirical antimicrobials, characteristics of the empirical regimen and the clinical characteristics of patients at the time of starting antimicrobials, patterns of changes to empirical therapy at different timepoints, and modifiable factors associated with changes to the initial empirical regimen in the first 5 days of therapy.
We did a chart review of adult inpatients receiving one or more antimicrobials in six US hospitals on 4 days during 2009 and 2010. Our primary outcome was the modification of antimicrobial regimen on or before the 5th day of empirical therapy, analysed as a three-category variable. Bivariate analyses were used to establish demographic and clinical variables associated with the outcome. Variables with p values below 0·1 were included in a multivariable generalised linear latent and mixed model with multinomial logit link to adjust for clustering within hospitals and accommodate a non-binary outcome variable.
Across the six study sites, 4119 (60%) of 6812 inpatients received antimicrobials. Of 1200 randomly selected patients with active antimicrobials, 730 (61%) met inclusion criteria. At the start of therapy, 220 (30%) patients were afebrile and had normal white blood cell counts. Appropriate cultures were collected from 432 (59%) patients, and 250 (58%) were negative. By the 5th day of therapy, 12·5% of empirical antimicrobials were escalated, 21·5% were narrowed or discontinued, and 66·4% were unchanged. Narrowing or discontinuation was more likely when cultures were collected at the start of therapy (adjusted OR 1·68, 95% CI 1·05-2·70) and no infection was noted on an initial radiological study (1·76, 1·11-2·79). Escalation was associated with multiple infection sites (2·54, 1·34-4·83) and a positive culture (1·99, 1·20-3·29).
Broad-spectrum empirical therapy is common, even when clinical signs of infection are absent. Fewer than one in three inpatients have their regimens narrowed within 5 days of starting empirical antimicrobials. Improved diagnostic methods and continued education are needed to guide discontinuation of antimicrobials.
US Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion; Robert Wood Johnson Foundation; US Department of Veterans Administration; US Department of Homeland Security.
建议根据培养结果或临床症状适时调整经验性抗菌药物的使用,以控制抗菌药物的过度使用和耐药性。我们旨在评估患者开始使用经验性抗菌药物的频率、经验性治疗方案的特点以及开始使用抗菌药物时患者的临床特征、不同时间点经验性治疗的变化模式,以及治疗前5天内与初始经验性治疗方案变化相关的可改变因素。
我们对2009年和2010年期间美国六家医院在4天内接受一种或多种抗菌药物治疗的成年住院患者进行了病历审查。我们的主要结局是在经验性治疗的第5天或之前对抗菌药物治疗方案的调整,作为一个三类变量进行分析。采用双变量分析确定与该结局相关的人口统计学和临床变量。将p值低于0.1的变量纳入多变量广义线性潜在混合模型,采用多项logit链接来调整医院内的聚类情况,并处理非二元结局变量。
在六个研究地点,6812名住院患者中有4119名(60%)接受了抗菌药物治疗。在随机选择的1200名正在使用抗菌药物的患者中,730名(61%)符合纳入标准。在治疗开始时,220名(30%)患者无发热且白细胞计数正常。432名(59%)患者采集了适当的培养样本,其中250名(58%)培养结果为阴性。到治疗第5天时,12.5%的经验性抗菌药物治疗方案升级,21.5%的方案缩小或停用,66.4%的方案未改变。当在治疗开始时采集培养样本(调整后的比值比为1.68,95%置信区间为1.05 - 2.70)且初始影像学检查未发现感染时(1.76,1.11 - 2.79),更有可能缩小或停用抗菌药物。治疗方案升级与多个感染部位(2.54,1.34 - 4.83)和培养结果阳性(1.99,1.20 - 3.29)有关。
即使没有感染的临床症状,广谱经验性治疗也很常见。在开始经验性抗菌药物治疗的5天内,不到三分之一的住院患者缩小了其治疗方案。需要改进诊断方法并持续开展教育以指导抗菌药物的停用。
美国疾病控制与预防中心医疗质量促进司;罗伯特·伍德·约翰逊基金会;美国退伍军人事务部;美国国土安全部。